Skip to NavigationSkip to content

Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure

Published on 16/12/19 at 11:28am

Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed that the drug failed to meet its primary endpoint in the treatment of progressive supranuclear palsy (PSP).

The findings of the study showed that gosuranemab did not offer “statistically significant” clinical benefit in the disease as indicated on the PSP rating scale (PSPRS) after 52 weeks of treatment. The company also noted that the study failed to show efficacy on the key clinical secondary endpoints.

It was noted, however, that safety results for the therapy were consistent with previous findings, with data to be presented at a future event.

“We are disappointed with the efficacy results of the Phase 2 PASSPORT study,” said Dr Alfred Sandrock Jr, Executive Vice President, Research and Development and Chief Medical Officer at Biogen. “We remain unwavering in our commitment to advancing therapies that have the potential to address the significant unmet medical needs of people with neurodegenerative diseases who are faced with limited to no treatment options.”

Despite these trials terminations, Biogen confirmed it will continue evaluating the drug in the ongoing Phase 2 trial for the treatment of mild cognitive impairment due to Alzheimer’s disease.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches